E
ReShape Lifesciences Inc.
RSLS
$0.6355
$0.00050.08%
E
Sell
3/7/2025Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to E+ from E on 3/7/2025 due to an increase in the volatility index.
ReShape Lifesciences Inc. (RSLS) was upgraded to E+ from E on 3/7/2025 due to an increase in the volatility index.
E
Sell
2/20/2025Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to E from E+ on 2/20/2025 due to a decline in the volatility index, growth index and solvency index. Debt to equity increased from 0.04 to 0.08, and the quick ratio declined from 0.76 to 0.52.
ReShape Lifesciences Inc. (RSLS) was downgraded to E from E+ on 2/20/2025 due to a decline in the volatility index, growth index and solvency index. Debt to equity increased from 0.04 to 0.08, and the quick ratio declined from 0.76 to 0.52.
E
Sell
10/11/2024Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to E+ from E on 10/11/2024 due to a noticeable increase in the valuation index and volatility index.
ReShape Lifesciences Inc. (RSLS) was upgraded to E+ from E on 10/11/2024 due to a noticeable increase in the valuation index and volatility index.
E
Sell
9/26/2024Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to E from E+ on 9/26/2024 due to a noticeable decline in the valuation index, volatility index and solvency index. Debt to equity increased from 0.02 to 0.04, and the quick ratio declined from 1.12 to 0.76.
ReShape Lifesciences Inc. (RSLS) was downgraded to E from E+ on 9/26/2024 due to a noticeable decline in the valuation index, volatility index and solvency index. Debt to equity increased from 0.02 to 0.04, and the quick ratio declined from 1.12 to 0.76.
E
Sell
8/1/2024Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to E+ from E on 8/1/2024 due to an increase in the volatility index and growth index.
ReShape Lifesciences Inc. (RSLS) was upgraded to E+ from E on 8/1/2024 due to an increase in the volatility index and growth index.
E
Sell
7/17/2024Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to E from E+ on 7/17/2024 due to a decline in the volatility index.
ReShape Lifesciences Inc. (RSLS) was downgraded to E from E+ on 7/17/2024 due to a decline in the volatility index.
E
Sell
6/26/2024Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to E+ from E on 6/26/2024 due to an increase in the volatility index and total return index.
ReShape Lifesciences Inc. (RSLS) was upgraded to E+ from E on 6/26/2024 due to an increase in the volatility index and total return index.
E
Sell
6/10/2024Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to E from E+ on 6/10/2024 due to a decline in the growth index, volatility index and solvency index. The quick ratio declined from 1.62 to 1.12, EBIT declined 16.62% from -$1.9M to -$2.21M, and total revenue declined 1.92% from $1.98M to $1.94M.
ReShape Lifesciences Inc. (RSLS) was downgraded to E from E+ on 6/10/2024 due to a decline in the growth index, volatility index and solvency index. The quick ratio declined from 1.62 to 1.12, EBIT declined 16.62% from -$1.9M to -$2.21M, and total revenue declined 1.92% from $1.98M to $1.94M.
E
Sell
6/4/2024Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to E+ from E on 6/4/2024 due to an increase in the volatility index and total return index.
ReShape Lifesciences Inc. (RSLS) was upgraded to E+ from E on 6/4/2024 due to an increase in the volatility index and total return index.
E
Sell
5/17/2024Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to E from E+ on 5/17/2024 due to a decline in the volatility index.
ReShape Lifesciences Inc. (RSLS) was downgraded to E from E+ on 5/17/2024 due to a decline in the volatility index.
E
Sell
4/29/2024Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to E+ from E on 4/29/2024 due to an increase in the volatility index.
ReShape Lifesciences Inc. (RSLS) was upgraded to E+ from E on 4/29/2024 due to an increase in the volatility index.
E
Sell
4/12/2024Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to E from E+ on 4/12/2024 due to a noticeable decline in the solvency index and volatility index.
ReShape Lifesciences Inc. (RSLS) was downgraded to E from E+ on 4/12/2024 due to a noticeable decline in the solvency index and volatility index.
E
Sell
4/1/2024Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to E+ from E on 4/1/2024 due to a major increase in the solvency index, volatility index and total return index.
ReShape Lifesciences Inc. (RSLS) was upgraded to E+ from E on 4/1/2024 due to a major increase in the solvency index, volatility index and total return index.
E
Sell
3/14/2024Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to E from E+ on 3/14/2024 due to a decline in the volatility index.
ReShape Lifesciences Inc. (RSLS) was downgraded to E from E+ on 3/14/2024 due to a decline in the volatility index.
E
Sell
2/23/2024Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to E+ from E on 2/23/2024 due to an increase in the volatility index.
ReShape Lifesciences Inc. (RSLS) was upgraded to E+ from E on 2/23/2024 due to an increase in the volatility index.
E
Sell
2/7/2024Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to E from E+ on 2/7/2024 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from 0.02 to 0.04, and the quick ratio declined from 1.49 to 0.81.
ReShape Lifesciences Inc. (RSLS) was downgraded to E from E+ on 2/7/2024 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from 0.02 to 0.04, and the quick ratio declined from 1.49 to 0.81.
E
Sell
3/14/2023Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to E+ from D- on 03/14/2023.
ReShape Lifesciences Inc. (RSLS) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to D- from E+ on 02/23/2023.
ReShape Lifesciences Inc. (RSLS) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index, solvency index and volatility index. The quick ratio declined from 1.52 to 1.11, earnings per share declined from -$24.7942 to -$26.178, and total revenue declined 3.25% from $2.89M to $2.8M.
ReShape Lifesciences Inc. (RSLS) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index, solvency index and volatility index. The quick ratio declined from 1.52 to 1.11, earnings per share declined from -$24.7942 to -$26.178, and total revenue declined 3.25% from $2.89M to $2.8M.
D
Sell
11/10/2022Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 11/10/2022 due to a decline in the volatility index.
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 11/10/2022 due to a decline in the volatility index.
D
Sell
10/21/2022Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 10/21/2022 due to an increase in the volatility index.
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 10/21/2022 due to an increase in the volatility index.
D
Sell
10/6/2022Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 10/6/2022 due to a decline in the volatility index.
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 10/6/2022 due to a decline in the volatility index.
D
Sell
9/9/2022Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 9/9/2022 due to an increase in the volatility index.
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 9/9/2022 due to an increase in the volatility index.
D
Sell
8/24/2022Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 8/24/2022 due to a decline in the solvency index and volatility index. The quick ratio declined from 2.19 to 1.52.
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 8/24/2022 due to a decline in the solvency index and volatility index. The quick ratio declined from 2.19 to 1.52.
D
Sell
8/4/2022Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 8/4/2022 due to an increase in the volatility index.
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 8/4/2022 due to an increase in the volatility index.
D
Sell
7/20/2022Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 7/20/2022 due to a decline in the volatility index and total return index.
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 7/20/2022 due to a decline in the volatility index and total return index.
D
Sell
6/29/2022Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 6/29/2022 due to an increase in the volatility index.
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 6/29/2022 due to an increase in the volatility index.
D
Sell
6/13/2022Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 6/13/2022 due to a decline in the volatility index.
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 6/13/2022 due to a decline in the volatility index.
D
Sell
5/26/2022Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 5/26/2022 due to an increase in the solvency index, growth index and volatility index. Earnings per share increased from -$1.9838 to -$0.4431.
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 5/26/2022 due to an increase in the solvency index, growth index and volatility index. Earnings per share increased from -$1.9838 to -$0.4431.
D
Sell
5/16/2022Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to D- from E+ on 5/16/2022 due to an increase in the volatility index.
ReShape Lifesciences Inc. (RSLS) was upgraded to D- from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
ReShape Lifesciences Inc. (RSLS) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/27/2022Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to D from E+ on 4/27/2022 due to an increase in the volatility index.
ReShape Lifesciences Inc. (RSLS) was upgraded to D from E+ on 4/27/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and volatility index.
ReShape Lifesciences Inc. (RSLS) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and volatility index.
D
Sell
11/17/2021Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 11/17/2021 due to a significant decline in the growth index and total return index. EBIT declined 486% from -$2.56M to -$14.98M, and earnings per share declined from -$0.6995 to -$1.48.
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 11/17/2021 due to a significant decline in the growth index and total return index. EBIT declined 486% from -$2.56M to -$14.98M, and earnings per share declined from -$0.6995 to -$1.48.
D
Sell
11/9/2021Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
ReShape Lifesciences Inc. (RSLS) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
E
Sell
11/8/2021Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to E+ from D on 11/8/2021 due to a noticeable decline in the solvency index and valuation index. The quick ratio declined from 0.27 to 0.2, and debt to equity increased from 0.9 to 1.07.
ReShape Lifesciences Inc. (RSLS) was downgraded to E+ from D on 11/8/2021 due to a noticeable decline in the solvency index and valuation index. The quick ratio declined from 0.27 to 0.2, and debt to equity increased from 0.9 to 1.07.
D
Sell
10/28/2020Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 10/28/2020 due to an increase in the volatility index and total return index.
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 10/28/2020 due to an increase in the volatility index and total return index.
D
Sell
10/13/2020Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 10/13/2020 due to a decline in the volatility index.
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 10/13/2020 due to a decline in the volatility index.
D
Sell
9/1/2020Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 9/1/2020 due to an increase in the volatility index and growth index.
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 9/1/2020 due to an increase in the volatility index and growth index.
D
Sell
8/17/2020Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 8/17/2020 due to a decline in the growth index and solvency index. Debt to equity increased from 0.28 to 0.44, total revenue declined 38.97% from $2.79M to $1.7M, and the quick ratio declined from 0.48 to 0.36.
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 8/17/2020 due to a decline in the growth index and solvency index. Debt to equity increased from 0.28 to 0.44, total revenue declined 38.97% from $2.79M to $1.7M, and the quick ratio declined from 0.48 to 0.36.
D
Sell
7/13/2020Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 7/13/2020 due to an increase in the total return index.
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 7/13/2020 due to an increase in the total return index.
D
Sell
6/26/2020Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 6/26/2020 due to a decline in the volatility index.
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 6/26/2020 due to a decline in the volatility index.
D
Sell
6/2/2020Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 6/2/2020 due to a noticeable increase in the growth index, valuation index and volatility index.
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 6/2/2020 due to a noticeable increase in the growth index, valuation index and volatility index.
D
Sell
5/15/2020Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 5/15/2020 due to a large decline in the growth index, valuation index and volatility index. Operating cash flow declined 145.65% from -$1.32M to -$3.25M, and total revenue declined 31.14% from $4.05M to $2.79M.
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 5/15/2020 due to a large decline in the growth index, valuation index and volatility index. Operating cash flow declined 145.65% from -$1.32M to -$3.25M, and total revenue declined 31.14% from $4.05M to $2.79M.
D
Sell
5/4/2020Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 5/4/2020 due to a substantial increase in the solvency index, growth index and volatility index. Earnings per share increased from -$106.4427 to -$3.9845, operating cash flow increased 69.14% from -$4.28M to -$1.32M, and total revenue increased 15.22% from $3.52M to $4.05M.
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 5/4/2020 due to a substantial increase in the solvency index, growth index and volatility index. Earnings per share increased from -$106.4427 to -$3.9845, operating cash flow increased 69.14% from -$4.28M to -$1.32M, and total revenue increased 15.22% from $3.52M to $4.05M.
D
Sell
4/22/2020Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 4/22/2020 due to a large decline in the solvency index, volatility index and total return index.
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 4/22/2020 due to a large decline in the solvency index, volatility index and total return index.
D
Sell
4/3/2020Upgraded
ReShape Lifesciences Inc. (RSLSD) was upgraded to D from D- on 4/3/2020 due to an increase in the volatility index.
ReShape Lifesciences Inc. (RSLSD) was upgraded to D from D- on 4/3/2020 due to an increase in the volatility index.
D
Sell
3/19/2020Downgrade
ReShape Lifesciences Inc. (RSLSD) was downgraded to D- from D on 3/19/2020 due to a decline in the volatility index and growth index.
ReShape Lifesciences Inc. (RSLSD) was downgraded to D- from D on 3/19/2020 due to a decline in the volatility index and growth index.
D
Sell
11/15/2019Upgraded
ReShape Lifesciences Inc. (RSLSD) was upgraded to D from D- on 11/15/2019 due to a large increase in the efficiency index and growth index. Earnings per share increased from -$150.2454 to -$106.4427.
ReShape Lifesciences Inc. (RSLSD) was upgraded to D from D- on 11/15/2019 due to a large increase in the efficiency index and growth index. Earnings per share increased from -$150.2454 to -$106.4427.
D
Sell
6/5/2018Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 6/5/2018 due to a decline in the efficiency index, growth index and solvency index. The quick ratio declined from 1.51 to 0.21, net income declined 16.8% from -$9.62M to -$11.23M, and total capital declined 13.74% from $76.37M to $65.87M.
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 6/5/2018 due to a decline in the efficiency index, growth index and solvency index. The quick ratio declined from 1.51 to 0.21, net income declined 16.8% from -$9.62M to -$11.23M, and total capital declined 13.74% from $76.37M to $65.87M.
D
Sell
1/22/2018Upgraded
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 1/22/2018 due to an increase in the volatility index.
ReShape Lifesciences Inc. (RSLS) was upgraded to D from D- on 1/22/2018 due to an increase in the volatility index.
D
Sell
1/5/2018Downgrade
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 1/5/2018 due to a noticeable decline in the growth index and volatility index. Earnings per share declined from -$0.9118 to -$1.0552.
ReShape Lifesciences Inc. (RSLS) was downgraded to D- from D on 1/5/2018 due to a noticeable decline in the growth index and volatility index. Earnings per share declined from -$0.9118 to -$1.0552.
D
Sell
8/14/2017Upgraded
EnteroMedics Inc. (ETRM) was upgraded to D from E+ on 8/14/2017 due to an increase in the efficiency index, growth index and solvency index. Total revenue increased 132.75% from $40 to $93.1, total capital increased 111.78% from $17.95M to $38.01M, and earnings per share increased from -$1.2727 to -$0.9118.
EnteroMedics Inc. (ETRM) was upgraded to D from E+ on 8/14/2017 due to an increase in the efficiency index, growth index and solvency index. Total revenue increased 132.75% from $40 to $93.1, total capital increased 111.78% from $17.95M to $38.01M, and earnings per share increased from -$1.2727 to -$0.9118.
E
Sell
8/9/2017Downgrade
EnteroMedics Inc. (ETRM) was downgraded to E+ from D- on 8/9/2017 due to a decline in the volatility index.
EnteroMedics Inc. (ETRM) was downgraded to E+ from D- on 8/9/2017 due to a decline in the volatility index.
D
Sell
5/17/2017Downgrade
EnteroMedics Inc. (ETRM) was downgraded to D- from D on 5/17/2017 due to a decline in the total return index.
EnteroMedics Inc. (ETRM) was downgraded to D- from D on 5/17/2017 due to a decline in the total return index.
D
Sell
3/13/2017Upgraded
EnteroMedics Inc. (ETRM) was upgraded to D from E+ on 3/13/2017 due to a large increase in the growth index, volatility index and total return index. Earnings per share increased from -$11.7728 to -$2.6516, operating cash flow increased 23.74% from -$4.63M to -$3.53M, and EBIT increased 7.49% from -$4.46M to -$4.13M.
EnteroMedics Inc. (ETRM) was upgraded to D from E+ on 3/13/2017 due to a large increase in the growth index, volatility index and total return index. Earnings per share increased from -$11.7728 to -$2.6516, operating cash flow increased 23.74% from -$4.63M to -$3.53M, and EBIT increased 7.49% from -$4.46M to -$4.13M.
E
Sell
7/8/2016Downgrade
EnteroMedics Inc. (ETRM) was downgraded to E+ from D- on 7/8/2016 due to a decline in the volatility index and total return index.
EnteroMedics Inc. (ETRM) was downgraded to E+ from D- on 7/8/2016 due to a decline in the volatility index and total return index.
D
Sell
5/19/2016Upgraded
EnteroMedics Inc. (ETRM) was upgraded to D- from E+ on 5/19/2016 due to an increase in the efficiency index. Total capital increased 92.22% from $4.94M to $9.5M.
EnteroMedics Inc. (ETRM) was upgraded to D- from E+ on 5/19/2016 due to an increase in the efficiency index. Total capital increased 92.22% from $4.94M to $9.5M.
E
Sell
4/1/2016Downgrade
EnteroMedics Inc. (ETRM) was downgraded to E+ from D- on 4/1/2016 due to a decline in the growth index, solvency index and efficiency index. Net income declined 63.11% from -$4.15M to -$6.77M, earnings per share declined from -$0.5988 to -$0.9529, and the quick ratio declined from 3.34 to 1.78.
EnteroMedics Inc. (ETRM) was downgraded to E+ from D- on 4/1/2016 due to a decline in the growth index, solvency index and efficiency index. Net income declined 63.11% from -$4.15M to -$6.77M, earnings per share declined from -$0.5988 to -$0.9529, and the quick ratio declined from 3.34 to 1.78.
D
Sell
3/11/2016Downgrade
EnteroMedics Inc. (ETRM) was downgraded to D- from D on 3/11/2016 due to a significant decline in the total return index, volatility index and solvency index.
EnteroMedics Inc. (ETRM) was downgraded to D- from D on 3/11/2016 due to a significant decline in the total return index, volatility index and solvency index.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
